Featured Publications
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
Prunas O, Warren JL, Crawford FW, Gazit S, Patalon T, Weinberger DM, Pitzer VE. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. Science 2022, 375: eabl4292. PMID: 35084937, PMCID: PMC9261115, DOI: 10.1126/science.abl4292.Peer-Reviewed Original ResearchConceptsVaccine effectivenessSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Effectiveness of vaccinesEffectiveness of vaccinationTotal vaccine effectivenessSARS-CoV-2Household contactsSecond doseCoronavirus 2Household transmissionDelta variantDay 10VaccinationBNT162b2COVID-19InfectionChain binomial modelVaccineDoseImmunity
2022
Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel
Prunas O, Weinberger D, Pitzer V, Gazit S, Patalon T. Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel. Clinical Infectious Diseases 2022, 76: 113-118. PMID: 36484301, PMCID: PMC10202431, DOI: 10.1093/cid/ciac315.Peer-Reviewed Original ResearchConceptsMaccabi Healthcare ServicesBNT162b2 vaccineSecond doseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionPositive polymerase chain reaction testSARS-CoV-2 infectionPfizer BNT162b2 vaccineCoronavirus 2 infectionVaccine-induced immunityVaccine-induced protectionPolymerase chain reaction testIncidence of infectionCoronavirus disease 2019COVID-19Chain reaction testShort-term effectivenessCase-control designLong-term effectivenessVaccine effectivenessSymptomatic infectionLong-term protectionDisease 2019Delta variantPredicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data
Ryman J, Weaver J, Hu T, Weinberger D, Yee K, Sachs J. Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data. Npj Vaccines 2022, 7: 140. PMID: 36344529, PMCID: PMC9640717, DOI: 10.1038/s41541-022-00538-1.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineSerotype-specific IgG concentrationsInvasive pneumococcal diseaseVaccine effectivenessIgG concentrationsPneumococcal diseaseImmune responseAntibody concentrationsProtective antibody concentrationsNext-generation vaccinesPCV13 recipientsConjugate vaccineImmunogenicity dataPCV7PCV13SerotypesVaccineDiseasePlaceboImmunogenicityRecipients